ACTHRD™ Identifies Patients Who May Benefit from PARP Inhibitor Treatment

PARP inhibitors have made major breakthroughs in personalized cancer treatment over the past few years. With the recent U.S. FDA approvals, genetic testing can now be used in patients with ovarian, breast, prostate, and pancreatic cancer to identify individuals who would likely benefit from PARP inhibitor treatment.

Mutations in HRR Genes Lead to HRD

A functional homologous recombination repair (HRR) system is required for proper repair of double-strand breaks (DSBs), which if left unrepaired are detrimental to living cells. Many genes are involved in the HRR mechanism, including the commonly known BRCA1 and BRCA2, as well as other HRR genes such as ATM, CHEK2, PALB2, and RAD51. When any of these HRR genes becomes mutated and unable to carry out its usual functions, homologous recombination deficiency (HRD) ensues. Cancer cells with HRD inevitably exhibit genome instability as a phenotype and loss of heterozygosity (LOH) is often observed in these cells. LOH occurs when a cancer cell that is originally heterozygous at a locus loses one of its two alleles at that locus. Therefore, LOH can be used as an indicator to assess the HRD status in cancer cells.

PARP Inhibitor Treatment

PARP inhibitors are pharmacological agents that block the activity of a family of DNA damage repair (DDR) proteins called PARPs, which are responsible for repairing single-strand breaks before DNA replication and cell division. If the single-strand breaks remain unrepaired and persist through the DNA replication process, double-strand breaks are formed as a result. PARP inhibitors cause the formation of double-strand breaks by trapping at the sites of single-strand DNA breaks.

In tumors with homologous recombination repair (HRR) deficiency (also known as HRD, which is caused by mutations in BRCA1/2 or other HRR genes), these double-strand breaks cannot be properly repaired, ultimately leading to cell death in a phenomenon called synthetic lethality whereby the combination of two individually non-lethal defects (i.e., PARP inhibition and HRD) leads to a unique vulnerability.

Mutations in non-BRCA HRR Genes and Cancer

Besides the well-studied BRCA1 and BRCA2 genes, there is a horde of other HRR genes involved in the DNA repair process. Mutations in any of these non-BRCA HRR genes may also give rise to HRD and dysfunctional HRR system. Therefore, genetic testing of BRCA1/2 alone is not adequate to select patients who may benefit from PARP inhibitor treatment.



1. Venkitaraman AR. Annu Rev Pathol 2009; 4: 461-487.
2. Ford D, et al. Lancet. 1994;343:692-695.
3. Struewing JP, et al.N Engl J Med. 1997;336:1401-1408.
4. Li X, Heyer WD. Cell Res. 2008;18:99-113.
5. Lord CJ, Ashworth A. Nat Rev Cancer. 2016;16:110-120.
6. Hartwell LH, Szankasi P, Roberts CJ, et al. Science 1997; 278: 1064-1068.
7. Venkitaraman AR, . Science 2014; 343: 1470-1475
8. Livraghi L, Garber JE. BMC Med 2015; 13:188.
9. Farmer H, McCabe N, Lord CJ, et al.Nature 2005; 434: 917-921
10. Bryant HE, Schultz N, Thomas HD, et al. Nature 2005; 434: 913-917.

 Hallmark of ACTHRD

1. Complete Information on BRCA and HRR genes

A comprehensive BRCA1/2 and other HRR genes testing which includes coding exons and splicing regions. NGS technology is used to detect multiple mutation types such as single nucleotide variants (SNVs), small insertions and deletions (InDels), large genomic rearrangements (LGRs) through a proprietary algorithm (application in progress), copy number variants (CNVs), and LOH Status.

2. Up-to-date Bioinformatic Analysis based on International Databases

Bioinformatic analysis is carried out by a team of dedicated and experienced bioinformatians with solid clinical genetics background. Information extracted from international databases such as gnomAD, 1000 Genome, ClinVar, COSMIC, as well as ACT Genomics’ self-built ethnographic database, provide relevant interpretation and useful insights on the variants identified.

3. A Clear and Detailed Medical Report

The report provides recommendations in accordance with the latest ACMG Guidelines and AMP Guidelines, as well as other relevant information such as disease risk based on the currently available clinical literature.

4. Quality Guaranteed

All tests carried out by ACT Genomics are conducted in a CAP-certified laboratory, which has also garnered the LDTS (Laboratory Developed Tests and Services) certification by the Taiwan FDA.

5. Short turnaround time: 10 working days 



24 genes including BRCA1&BRCA 

Sensitivity - ACTHRD®


Specificity - ACTHRD®


Sample Types - ACTHRD®


Sequencing Mean Depth

≥ 1000 x